The estimated Net Worth of Richard S Serbin is at least $1.26 Million dollars as of 14 January 2021. Mr. Serbin owns over 10,000 units of Co-Diagnostics Inc stock worth over $3,150 and over the last 6 years he sold CODX stock worth over $1,187,600. In addition, he makes $72,750 as Independent Director at Co-Diagnostics Inc.
Sign up
Mr. Serbin CODX stock SEC Form 4 insiders trading
Richard has made over 6 trades of the Co-Diagnostics Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 10,000 units of CODX stock worth $102,900 on 14 January 2021.
The largest trade he's ever made was selling 50,000 units of Co-Diagnostics Inc stock on 19 May 2020 worth over $913,000. On average, Richard trades about 7,579 units every 13 days since 2019. As of 14 January 2021 he still owns at least 2,500 units of Co-Diagnostics Inc stock.
You can see the complete history of Mr. Serbin stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Richard Serbin biography
Richard S. Serbin serves as Independent Director of the Company. He currently serves as a consultant to many companies in the healthcare industry. He was the President of Corporate Development and In-House Legal Counsel at Life Science Institute, LLC, from June 1, 2013 to July 15, 2014. Mr. Serbin is a global strategy advisor, pharmacist and entrepreneur with credentials both in pharmacy and law, complemented by more than 40 years of service as an FDA regulatory attorney and patent attorney in the healthcare industry. He was appointed to the Advisory Board of Cure Pharmaceutical in January 2017 and has been a Member of Advisory Board at Prime Access, Inc. since September 2015. Mr. Serbin has been a Director at Rapid Nutrition Plc since November 18, 2014. He served as Director at Viropro Inc. from May 2013 to June 2014. He was Head of Business Advisory Board at Mazal Plant Pharmaceuticals Inc. from October 2006 to September 2007 and also served as its Member of Business Advisory Board. He served as Chief Executive Officer of Optigenex Inc. from July 2002 to September 15, 2005 and a director from July 2004 to September 2005. From January 1999 until July 2002 Mr. Serbin served as a consultant to various pharmaceutical companies. He served as the President of Bradley Pharmaceuticals. He served as Vice President of Corporate Development at Ortho Pharmaceuticals, a Johnson & Johnson subsidiary, and practiced Patent and FDA law at Revlon Johnson & Johnson and Schering-Plough. He served as Patent Attorney for Schering Plough Corporation and Chief FDA Counsel for Revlon Corporation and Johnson and Johnson Corporation. Subsequently, he worked at Revlon Corporation, as its Chief Food, Drug and Cosmetic Counsel. He founded Radius Scientific Corporation. He was J&J’s Vice President of Corporate Development, and later led a successful public offering venture based on technology developed at Stanford Medical School. Mr. Serbin spent a large portion of his career focusing on international markets and clients. While atSchool.
What is the salary of Richard Serbin?
As the Independent Director of Co-Diagnostics Inc, the total compensation of Richard Serbin at Co-Diagnostics Inc is $72,750. There are 4 executives at Co-Diagnostics Inc getting paid more, with Dwight H. Egan having the highest compensation of $676,875.
How old is Richard Serbin?
Richard Serbin is 75, he's been the Independent Director of Co-Diagnostics Inc since 2017. There are no older and 9 younger executives at Co-Diagnostics Inc.
What's Richard Serbin's mailing address?
Richard's mailing address filed with the SEC is 2401 S. FOOTHILL DRIVE SUITE D, , SALT LAKE CITY, UT, 84109.
Insiders trading at Co-Diagnostics Inc
Over the last 7 years, insiders at Co-Diagnostics Inc have traded over $2,459,090 worth of Co-Diagnostics Inc stock and bought 8,205 units worth $11,819,010 . The most active insiders traders include Reed L Benson, James B Nelson und Dwight H Egan. On average, Co-Diagnostics Inc executives and independent directors trade stock every 79 days with the average trade being worth of $38,652. The most recent stock trade was executed by Brian Lee Brown on 20 March 2023, trading 3,000 units of CODX stock currently worth $5,700.
What does Co-Diagnostics Inc do?
co-diagnostics, inc. is a molecular diagnostics company that has acquired certain unique, patented diagnostic testing technology. a utah corporation headquartered in sandy, utah, its primary business is to commercialize its unique, patented technology through sales, development and licensing. the technology is embodied in three patent applications and certain trade secrets, which make dna testing for diseases faster, higher in performance, and more cost efficient than traditional technologies of the past. the company has undertaken completely innovative approaches to develop novel molecular technologies using biophysical models and statistical bioinformatics. it has successfully developed and commercialized a series of assays in the infectious disease area to demonstrate the capability of its technology. the technology on which the inventions are based were created by reference to certain mathematical models invented, designed and refined by dr. brent c. satterfield. the inventions are
What does Co-Diagnostics Inc's logo look like?
Complete history of Mr. Serbin stock trades at Co-Diagnostics Inc
Co-Diagnostics Inc executives and stock owners
Co-Diagnostics Inc executives and other stock owners filed with the SEC include:
-
Dwight H. Egan,
Chairman, CEO & Pres -
Dwight Egan,
Chairman of the Board, President, Chief Executive Officer -
Reed Benson,
Chief Financial Officer, Secretary -
Brent Satterfield,
Chief Technology Officer -
Richard Serbin,
Independent Director -
James Nelson,
Independent Director -
Eugene Durenard,
Independent Director -
Edward Murphy,
Independent Director -
Dr. Brent C. Satterfield Ph.D.,
Co-Founder & Member of Scientific Advisory Board -
Cameron Gundry,
Head of Commercialization LATAM/EUR -
Dr. Mayuranki Almaula,
Sr. VP of Overseas Operations & Strategic Alliances -
Andrew Benson,
Head of Investor Relations -
Dr. Jesse Montgomery,
Chief Scientific Officer -
Brian L. Brown CPA,
CFO & Company Sec. -
Brian Lee Brown,
Chief Financial Officer -
Llc Reagents,,
-
2030 Capital, Llc America,
10% owner -
Ted Murphy,
-
Richard David Abbott,
President